2020 Annual Conference   |  July 22-24, 2020  |  Online

The Conference is Now Open!

The 2020 Cholangiocarcinoma Foundation Annual Conference.

July 22-24

Our online conference format will allow patients, caregivers, scientists, researchers, and healthcare providers from around the globe to convene without traveling to Salt Lake City. The event will continue to be the premier source for the presentation of cutting-edge research, innovative therapies, and patient education in the field of cholangiocarcinoma.

Registration is required. If you previously registered for the conference, you will need to re-register to access our new platform.

Your registration will give you access to conference materials and recordings as well as raffle tickets. The first 500 patients/caregivers registered (one per household) will receive a goodie bag packed with fun swag.

Thanks to the generosity of our sponsors, we are able to make this virtual conference and its recordings free for registered participants.

2020 Conference by the Numbers

  • 700+ Patients & Caregivers
  • 300+ Clinicians & Researchers
  • 400+ Industry Representatives & Sponsors
  • 42 Countries Represented
  • 49 States, DC & Puerto Rico
July 22-24, 2020
Conference Chairs
<b>Jesús M Banales, PhD</b><br />
Biodonostia Institute<br />San Sebastián, Spain

Jesús M Banales, PhD
Biodonostia Institute
San Sebastián, Spain

<b>Rachna T Shroff, MD, MS</b><br />
University of Arizona Cancer Center<br />Tucson, Arizona, USA

Rachna T Shroff, MD, MS
University of Arizona Cancer Center
Tucson, Arizona, USA

2020 Cholangiocarcinoma Foundation Annual Conference

The 2020 Conference will build upon the foundation laid at this year\'s meeting as key opinion leaders both nationally and internationally, come together to collaborate and exchange knowledge. The program will seek to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by:


Increasing the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma

A New Perspective

Identifying gaps and gathering consensus on rapidly changing advances in basic, translational, and clinical research


Stimulating interdisciplinary cross-cooperation and sharing best practices by developing, strengthening, and supporting collaborations


Fostering dialogue and inspiring innovation across the world

Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers-having experienced the disease firsthand-will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.

Who Should Attend?

Who Should Attend?

  • Researchers
  • Physicians
  • Oncologists
  • Radiologists
  • Surgeons

  • Gastroenterologists
  • Hepatologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies

  • Government Regulators
  • Policymakers
  • Patients, Caregivers and others invested in the field of cholangiocarcinoma

Frequently Asked Questions

Incredible Numbers from our 2019 Conference


from 40 states and 12 countries representing healthcare, industry, patient advocacy organizations, patients, caregivers, academia and supporters.


including those by researchers, surgeons, patients, caregivers and industry specialists.


Medical Institutions

represented, including international key opinion leaders advancing cholangiocarcinoma research, treatment and care.


  • 200+ patients/caregivers
  • 29 poster presentations
  • 1,612 webcast attendees

with support from

  • 30 organizations: Agios, ASLAN Pharmaceuticals, Basiliea
    Pharmaceutica, Bayer, Beigene, Boston-Scientific, Bristol-Myers Squibb, Caris Life Sciences, Daiichi-Sankyo, DebiopharmGroup, EMD Serono, Foundation Medicine, Fujifilm, Incyte, Halozyme, Klus Pharma, Leap Therapeutics, Lexicon Pharmaceuticals, Merck, MundiPharma, NuCana, PCI Biotech, Pieris Pharmaceuticals, QED Therapeutics, RedHill Biopharma, Shepherd Therapeutics, Sirtex, Taiho Oncology, TriSalus Life Sciences, Zymeworks.